Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hCG vs Progesterone for Unexplained Recurrent Pregnancy Loss
NCT05365464Phase 2Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- May 2022
- Primary completion
- Dec 2025
- Modality
- rProtein (Recombinant Protein), Hormone, Biologic
01
Overview
Phase 2, randomised, open-label trial of recombinant human chorionic gonadotrophin in recurrent pregnancy loss (RPL) (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoints: Miscarriage Rate and Ongoing Pregnancy Rate at 8 weeks. Planned start May 2022; status: withdrawn.
02
Drugs
recombinant human chorionic gonadotrophin
03
Conditions
recurrent pregnancy loss (RPL)
Beyond the preview
Go deeper on NCT05365464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05365464.